Onkologie, Hämatologie - Daten und Informationen

10 Literatur des Artikels zu myelodysplastischen Syndromen

Autor/en: F. Nolte, S. Klein, H.-J. Fricke, A. Fabarius, W.-K. Hofmann
Letzte Änderung: 30.05.2012
  • Bennett JM, Catovsky D, Daniel MT, et al.
    Proposal for the classification of the myelodysplastic syndromes.
    Br J Haematol. 1982;51:189-199. PMID:6952920.

  • Bennett JM.
    Consensus statement on iron overload in myelodysplastic syndromes.
    Am J Hematol. 2008;83:858-861. PMID:18767130.

  • Deeg HJ.
    Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS).
    Hematology Am Soc Hematol Educ Program. 2005;167-173. PMID:16304376.

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al.
    Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
    Lancet Oncol. 2009;10:223-232. PMID:19230772.

  • Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D.
    Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
    J Hematol Oncol. 2012;5:12. PMID:22436456.

  • Germing U, Hildebrandt B, Pfeilstocker M et al.
    Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
    Leukemia. 2005;19:2223-2231. PMID:16193087.

  • Germing U, Strupp C, Kundgen A et al.
    No increase in age-specific incidence of myelodysplastic syndromes.
    Haematologica. 2004;89:905-910. PMID:15339672.

  • Greenberg P, Cox C, LeBeau MM et al.
    International scoring system for evaluating prognosis in myelodysplastic syndromes.
    Blood. 1997;89:2079-2088. PMID:9058730.

  • Haase D, Germing U, Schanz J et al.
    New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.
    Blood. 2007;110:4385-4395. PMID:17726160.

  • Hellstrom-Lindberg E, Negrin R, Stein R et al.
    Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
    Br J Haematol. 1997;99:344-351. PMID:9375752.

  • Hofmann WK, Heil G, Zander C et al.
    Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Ann Hematol. 2004;83:498-503. PMID:15156346.

  • Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G, et al.
    TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
    J Clin Oncol. 2011;29:1971-1979. PMID:21519010.

  • Knipp S, Hildebrand B, Kundgen A et al.
    Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Cancer. 2007;110:345-352. PMID:17559141.

  • Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al.
    TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
    Blood. 2009;114:3285-3291. PMID:19666869.

  • Kündgen A, Knipp S, Fox F et al.
    Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2005;84 Suppl 1:61-66. PMID:16270213.

  • List A, Dewald G, Bennett J et al.
    Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
    N Engl J Med. 2006;355:1456-1465. PMID:17021321.

  • List A, Kurtin S, Roe DJ et al.
    Efficacy of lenalidomide in myelodysplastic syndromes.
    N Engl J Med. 2005;352:549-557. PMID:15703420.

  • Malcovati L, Germing U, Kuendgen A et al.
    Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
    J Clin Oncol. 2007;25:3503-3510. PMID:17687155.

  • Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al.
    Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Blood. 2011;118:6239-46. PMID:21998214.

  • Malcovati L.
    Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Leuk Res. 2007;31 Suppl 3:2-6. PMID:18037415.

  • McClune BL, Weisdorf DJ, Pedersen TL et al.
    Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
    J Clin Oncol. 2010;28:1878-1887. PMID:20212255.

  • Molldrem JJ, Leifer E, Bahceci E et al.
    Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.
    Ann Intern Med. 2002;137:156-163. PMID:12160363.

  • Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al.
    Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
    N Engl J Med. 2011;365:1384-1395. PMID:21995386.

  • Passweg JR, Giagounidis A, Simcock M et al.
    Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
    J Clin Oncol. 2011;29:303-309. PMID:21149672.

  • Platzbecker U, Aul C, Ehninger G, Giagounidis A.
    Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil.
    Ann Hematol. 2010;89:427-428. PMID:19714330.

  • Platzbecker U, Finke J, Trenschel R et al.
    Supportive Care Only Versus Allogeneic Hematopoietic Cell Transplantation in Patients >/= 60 Years with De Novo High-Risk MDS.
    ASH Annual Meeting Abstracts. 2009;114:596.

  • Raza A, Reeves JA, Feldman EJ et al.
    Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
    Blood. 2008;111:86-93. PMID:17893227.

  • Rose C, Brechignac S, Vassilief D et al.
    Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM.
    Leuk Res. 2010;34:864-70. PMID:20129667.

  • Schanz J, Steidl C, Fonatsch C et al.
    Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
    J Clin Oncol. 2011;29:1963-1970. PMID:21519021.

  • Sloand EM, Olnes MJ, Weinstein B, Scheinberg P, Young NS.
    Alemtuzumab Treatment of Intermediate-1 (INT-1) Myelodysplasia Patients Is Associated with Sustained Improvement in Blood Counts and Cytogenetic Remissions.
    ASH Annual Meeting Abstracts. 2009;114:116.

  • Stadler M, Germing U, Kliche KO et al.
    A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
    Leukemia. 2004;18:460-465. PMID:14712285.

  • Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al.
    Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    J Clin Oncol. 2011;29:2499-2506. PMID:21576631.

  • Vardiman JW, Thiele J, Arber DA et al.
    The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
    Blood. 2009;114:937-951. PMID:19357394.

  • Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al.
    Frequent pathway mutations of splicing machinery in myelodysplasia.
    Nature. 2011;478:64-69. PMID:21909114.

Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: